Tag

#Medical Regulatory Issues

Home » Medical Regulatory Issues

290 posts
Bookmark?Remove?

U.S. FDA clears new version of Abbott’s low-cost glucose monitor

(Reuters) – The U.S. Food and Drug Administration on Monday cleared a new version of Abbott Laboratories’ continuous glucose monitoring device, helping the company build upon the success of its fastest-growing diabetes product. FreeStyle Libre 2, which was app... More »

Bookmark?Remove?

Novartis wins conditional EU approval for gene therapy Zolgensma

ZURICH (Reuters) – Novartis won European approval for its gene therapy Zolgensma for the hereditary disease spinal muscular atrophy (SMA), the Swiss drugmaker said on Tuesday, adding it is in talks over price with countries in hopes of a quick launch. The Euro... More »

Bookmark?Remove?

UK trials new breathing aid developed by Mercedes Formula One

LONDON (Reuters) – A new version of a breathing aid that can help coronavirus patients has been developed in less a week by a team involving Mercedes Formula One, and is being trialed at London hospitals. Continuous Positive Airway Pressure (CPAP) devices have... More »

Bookmark?Remove?

Merck’s Keytruda wins U.S. FDA approval for bladder cancer

(Reuters) – The U.S. Food and Drug Administration said on Wednesday it approved Merck & Co Inc’s Keytruda for a hard-to-treat form of bladder cancer, making it the first new treatment for the cancer in more than two decades. The therapy was approved for patien... More »

Bookmark?Remove?

Eisai Inc announces U.S. approval for insomnia drug

(Reuters) – Japan-based drugmaker Eisai Co’s U.S. subsidiary announced on Sunday that it had received approval from the U.S. Food and Drug Administration for its insomnia treatment in adult patients. The agency approved the drug, Dayvigo, in doses of 5 mg and ... More »

Bookmark?Remove?

FDA approves Aquestive’s ALS treatment

(Reuters) – The U.S. Food and Drug Administration on Friday approved Aquestive Therapeutics’ treatment for neurological disorder amyotrophic lateral sclerosis (ALS). Shares of the company, which developed riluzole oral film (ROF) and will market the film under... More »

Bookmark?Remove?

Novartis sickle-cell drug gets U.S. FDA approval

(The Nov 16 story corrects to clarify in second graph that patients will be infused by a healthcare provider.) By John Miller and Carl O’Donnell (Reuters) – Novartis AG on Friday won U.S. approval for its experimental sickle cell disease drug, Adakveo, making ... More »

Bookmark?Remove?

BeiGene prices lymphoma drug at $12,935 for a 30-day supply

(Reuters) – China-based drugmaker BeiGene Ltd on Friday priced its drug, Brukinsa, to treat a rare form of lymphoma at $12,935 for a 30-day supply. The U.S. Food and Drug Administration on Thursday approved the drug, giving a boost to the company’s strategy of... More »

Bookmark?Remove?

Roche sets sights on Novartis, Biogen as SMA trial hits target

ZURICH (Reuters) – Roche’s bid to rival Biogen and Novartis in treating spinal muscular atrophy (SMA) got a lift on Monday when the Swiss drugmaker said its drug risdiplam improved motor function of patients in a key study. Roche, which plans to seek approval ... More »

Bookmark?Remove?

FDA downplays risks from already recalled heartburn drug Zantac

NEW YORK (Reuters) – The U.S. Food and Drug Administration on Friday downplayed the risk caused by contamination of the already recalled popular heartburn drug Zantac, and said its tests suggest it does not cause carcinogens to form after ingestion by patients... More »

Bookmark?Remove?

Trump nominates MD Anderson oncologist as U.S. FDA Commissioner

(Reuters) – U.S. President Donald Trump plans to nominate Dr. Stephen Hahn, chief medical executive of the University of Texas MD Anderson Cancer Center, to lead the Food and Drug Administration, the White House said on Friday. If confirmed, Hahn, a radiation ... More »

Bookmark?Remove?

FDA approves Alexion’s Ultomiris for another rare blood disease

(Reuters) – The U.S. Food and Drug Administration on Friday approved Alexion Pharmaceuticals Inc’s treatment for a second rare blood disorder, the company said. The treatment, Ultomiris, has already been approved in the United States, Japan and the European Un... More »

Bookmark?Remove?

Bangladesh bans heartburn drug ranitidine over cancer fears

DHAKA (Reuters) – Bangladesh’s drug regulatory authority on Sunday issued a ban on sales of popular heartburn drug ranitidine while it investigates a potential cancer-causing substance in the drug. The move comes after the U.S. Food and Drug Administration (FD... More »

Bookmark?Remove?

Targeted Amgen drug has low response rate in colon cancer in study

(Reuters) – An experimental Amgen Inc drug that targets a specific genetic mutation shrank tumors in just one of 12 patients with advanced colorectal cancer who were given the highest dose in a small, early-stage trial, the company said on Saturday. The cancer... More »

Bookmark?Remove?

U.S and European regulators reviewing safety of heartburn drugs…

(Reuters) – U.S. and European drug regulators said on Friday they are reviewing the safety of the widely taken heartburn drug ranitidine, commonly known by the brand name Zantac, after they found traces of a probable cancer-causing impurity in some versions of... More »

Bookmark?Remove?

Factbox: What we know about U.S. vaping illnesses

(Reuters) – U.S. public health officials are investigating more than 450 cases of severe lung illnesses and have confirmed at least five deaths related to electronic cigarette products including the devices and liquids used inside them. The Centers for Disease... More »

Bookmark?Remove?

Xeris Pharma’s low blood sugar treatment wins FDA approval

(Reuters) – The U.S. Food and Drug Administration has approved Xeris Pharmaceuticals Inc’s glucagon therapy that aims to treat severely low sugar levels in diabetes patients, the drugmaker said on Tuesday. The condition, called hypoglycemia, can cause acute co... More »

Bookmark?Remove?

J&J liable for $572 million in Oklahoma opioid epidemic trial-…

NORMAN, Okla./BOSTON (Reuters) – An Oklahoma judge on Monday ordered Johnson & Johnson (JNJ.N) to pay $572.1 million to the state for its part in fueling an opioid epidemic by deceptively marketing addictive painkillers, a sum that was substantially less than ... More »

Bookmark?Remove?

AbbVie prices new rheumatoid arthritis drug at $59,000 a year

(Reuters) – AbbVie Inc has priced its new rheumatoid arthritis treatment at $59,000 a year after gaining U.S. approval on Friday, a big boost for the drugmaker struggling with rising competition for Humira, its blockbuster therapy for the same condition. A fou... More »

Bookmark?Remove?

FDA approves Celgene’s bone marrow cancer treatment

(Reuters) – The U.S. Food and Drug Administration on Friday approved Celgene Corp’s Inrebic to treat certain rare forms of bone marrow cancer called myelofibrosis, making it the second approved drug to treat the disease. Inrebic belongs to a class of drugs kno... More »

Bookmark?Remove?

Amgen wins U.S. patent battle on arthritis drug Enbrel, thwarting…

(Reuters) – A U.S. judge on Friday upheld two patents relating to Amgen Inc’s blockbuster rheumatoid arthritis drug Enbrel, denying a challenge by Novartis AG, which is seeking to launch a copycat version. The decision was a relief to investors concerned about... More »

Bookmark?Remove?

Bayer mediator dismisses report of $8 billion Roundup settlement

NEW YORK/FRANKFURT (Reuters) – Bayer AG has not offered to pay billions of dollars to settle claims in the United States related to the Roundup herbicide, mediator Ken Feinberg said, dismissing a report to that effect which drove its shares as much as 11% high... More »

Bookmark?Remove?

U.S. FDA approves Daiichi Sankyo’s treatment for rare joint tumor

(Reuters) – The U.S. Food and Drug Administration on Friday approved Daiichi Sankyo Co Ltd’s treatment for adult patients with a type of rare, non-cancerous tumor affecting joints and limbs. The label for the treatment, Turalio, includes a boxed warning flaggi... More »

Bookmark?Remove?

Novartis heart drug fails trial, curbing growth prospects

ZURICH (Reuters) – Novartis’s heart failure drug Entresto failed a trial in a new use, the Swiss drugmaker said on Monday, calling into question billions of dollars in potential revenue and taking the shine off one of the company’s biggest growth prospects. Th... More »

Bookmark?Remove?

Bernie Sanders visits Canadian pharmacy, talks drug prices

WINDSOR, Ontario (Reuters) – U.S. Senator and Democratic presidential hopeful Bernie Sanders joined diabetes patients as they drove across the border on Sunday to buy cheap insulin in Canada, highlighting his argument in favor of federally negotiated prescript... More »

Bookmark?Remove?

Oklahoma, J&J to wrap up first trial over opioid crisis

(Reuters) – Oklahoma’s attorney general is expected on Monday to urge a judge to find Johnson & Johnson responsible for flooding the market with painkillers and fueling the U.S. opioid epidemic, as the first trial in nationwide litigation over the drug crisis ... More »

Bookmark?Remove?

FDA approves drug for loss of sexual desire in women

(Reuters) – The U.S. drug regulator on Friday approved Palatin Technologies and Amag Pharmaceuticals’ drug to restore sexual desire in premenopausal women, the latest attempt to come up with a therapy that some have dubbed as “female Viagra”. The therapy, Vyle... More »

Bookmark?Remove?

Israel’s Zebra Medical gets FDA ok for brain bleeds product

TEL AVIV (Reuters) – Zebra Medical Vision, an Israel medical imaging analytics company, said on Monday it received its third clearance from the U.S. Food and Drug Administration for its alert for intracranial hemorrhage, based on head CT scans. The latest clea... More »

Bookmark?Remove?

For Anderson family, an early bet on SMA gene therapy

NEW YORK (Reuters) – When Malachi Anderson was diagnosed with a rare and often deadly disease called spinal muscular atrophy (SMA) as an infant nearly four years ago, his parents Tina and Torence had a decision to make. In years past, many of the babies born w... More »

Bookmark?Remove?

U.S. FDA labels J&J surgical staplers’ recall as severest

(Reuters) – The U.S. Food and Drug Administration warned of risks of serious injury or death from surgical staplers made by Johnson & Johnson’s Ethicon unit, labeling a recent recall of the device as its most serious. The recall, initiated early April by Ethic... More »

Bookmark?Remove?

AbbVie halts enrollment after brain cancer trial misses goal,…

(Reuters) – AbbVie Inc said on Friday it has halted enrollment of patients in all ongoing studies testing its brain cancer treatment after the drug failed to meet the main goal in a late-stage trial. The company’s shares fell 1.8 percent to $78.10 before the b... More »

Bookmark?Remove?

U.S. states accuse Teva, other drugmakers, of price-fixing: lawsuit

WASHINGTON (Reuters) – U.S. states filed a lawsuit accusing Teva Pharmaceuticals USA Inc of orchestrating a sweeping scheme with 19 other drug companies to inflate drug prices – sometimes by more than 1,000% – and stifle competition for generic drugs, state pr... More »

Bookmark?Remove?

Congo records 1,000th Ebola death in current outbreak

GOMA, Democratic Republic of Congo (Reuters) – The death toll from the Ebola outbreak in Democratic Republic of Congo rose above 1,000 on Friday, as violent attacks on treatment centres hamper efforts to control the second-worst epidemic of the virus on record... More »

Bookmark?Remove?

Second death in Novartis gene therapy trials under investigation

(Reuters) – Novartis AG, which this week announced positive interim trial results for its experimental gene therapy for spinal muscular atrophy, on Friday said investigation is underway into whether a second trial death could be related to the treatment. Novar... More »

Bookmark?Remove?

FDA approves Teva’s generic nasal spray to treat opioid overdose

(Reuters) – Generic drugmaker Teva Pharmaceutical Industries Ltd on Friday received approval from the U.S. Food and Drug Administration (FDA) to market its generic nasal spray for opioid overdose, the health regulator said. This is the first approval of a gene... More »

Bookmark?Remove?

FDA rejects Sanofi-Lexicon add-on pill for type 1 diabetes

(Reuters) – The U.S. Food and Drug Administration declined to approve a drug developed by Sanofi SA and Lexicon Pharmaceuticals Inc intended for use with insulin in patients with type 1 diabetes, the companies said on Friday. The decision comes about two month... More »

Bookmark?Remove?

U.S. seeks to cut dialysis costs with more home care versus clinics

(Reuters) – The Trump administration is working on a new payment approach for treating kidney disease that favors lower cost care at home and transplants, a change that would upend a dialysis industry that provides care in thousands of clinics nationwide. The ... More »

Bookmark?Remove?

New cancer-causing toxin found in recalled blood pressure pills

(Reuters) – U.S. health regulators said on Friday a third cancer-causing toxin was found in some blood pressure pills recalled by India’s Hetero Labs Ltd a day earlier, adding to a global recall of commonly used drugs to treat hypertension. The U.S. Food and D... More »

Bookmark?Remove?

Endo gains on favorable FDA drug compounding decision

(Reuters) – Endo International Plc said on Friday the U.S. health regulator has decided not to include blood pressure treatment vasopressin in its list of drugs that can be used in compounding, in a boost to the drugmaker that makes the only FDA-approved versi... More »

Bookmark?Remove?

J&J becomes first drugmaker to add prices to television ads

CHICAGO (Reuters) – Johnson & Johnson said on Thursday it will start adding the price of its medicines to television commercials by next month, becoming the first drugmaker to heed a call by U.S. President Donald Trump for price transparency of drugs advertise... More »

Bookmark?Remove?

FDA chief to meet e-cigarette makers amid crackdown

(Reuters) – The U.S. Food and Drug Administration (FDA) plans to meet top-level executives of e-cigarette makers, the agency’s chief said on Thursday, hinting that some companies seem to be backing away from commitments related to youth’s access to e-cigarette... More »

Bookmark?Remove?

Merck KGaA-Pfizer to end late-stage ovarian cancer treatment study

(Reuters) – Merck KGaA and Pfizer Inc said on Friday they were ending a late-stage study for their drug to treat a form of ovarian cancer in previously untreated patients. The results showed the drug, Bavencio, in combination with, or as a follow-on treatment ... More »

Bookmark?Remove?

Alexion wins early U.S. approval for rare blood disorder drug

(Reuters) – The U.S. Food and Drug Administration approved on Friday Alexion Pharmaceuticals Inc’s rare blood disorder drug Ultomiris, an early backing that also solidifies the company’s dominant market position. The company’s flagship drug, Soliris, was the l... More »

Bookmark?Remove?

Norway biotech Ultimovacs plans IPO to develop cancer drug

OSLO (Reuters) – Norway’s Ultimovacs plans to raise around 700 million Norwegian crowns ($82 million) in an initial public offering in early 2019 to help fund the development of its immunotherapy cancer drug. “Our main investors are positive and will take a si... More »

Bookmark?Remove?

Dutch firm argenx, J&J affiliate to collaborate on cancer therapy

(Reuters) – Netherlands-based biopharmaceutical company argenx SE said it signed a deal with Cilag GmbH International, an affiliate of Johnson & Johnson’s Janssen Pharmaceutical Companies unit, to develop its Cusatuzumab drug in certain types of cancer. The de... More »

Bookmark?Remove?

Bayer hits back at new Netflix medical device documentary

NEW YORK (Reuters) – Bayer AG disputed accusations in a new Netflix documentary that claims medical device makers and the U.S. Food and Drug Administration placed profits before patient safety. The company, in a statement released Thursday night, said the docu... More »

Bookmark?Remove?

FDA staff raises efficacy doubts on GSK’s lung disease treatment

(Reuters) – U.S. Food and Drug Administration staff reviewers have raised doubts over the effectiveness of GlaxoSmithKline Plc’s drug Nucala in treating a disease that limits airflow to the lungs. Nucala, already approved for treating severe asthma patients, i... More »

Bookmark?Remove?

Bayer to phase out Essure birth control device in U.S.

NEW YORK (Reuters) – Life sciences company Bayer AG said on Friday it would discontinue the sale of its birth control product Essure in the United States, citing a decline in sales of the implantable device that made the business no longer sustainable. The dec... More »

Bookmark?Remove?

Agios Pharmaceuticals leukemia drug gets U.S. approval

(Reuters) – Agios Pharmaceuticals Inc said on Friday the U.S. Food and Drug Administration approved its treatment for a type of leukemia, the first targeted drug for patients with a specific genetic mutation. The company plans to launch the drug, Tibsovo, in t... More »

Bookmark?Remove?

Israeli firm gets U.S. nod for advanced trials for non-opiate…

JERUSALEM (Reuters) – Israeli pharmaceuticals company PainReform has received approval from the U.S. Food and Drug Administration (FDA) to begin late-stage clinical studies for a pain relief drug that is a departure from opiate-based narcotics, it said on Tues... More »

Bookmark?Remove?

CTI Biopharma’s cancer drug fails late-stage trial, shares tumble

(Reuters) – CTI Biopharma Corp said on Monday its treatment for a type of blood cancer did not meet the main goal of a late-stage trial, sending its shares down 17 percent. The drug, Pixuvri, did not show improvement in the length of time patients survived wit... More »

Bookmark?Remove?

AstraZeneca wins speedy approvals for cancer drugs in Japan

LONDON (Reuters) – AstraZeneca has won rapid regulatory approval for new uses of two of its important cancer drugs in Japan, less than six months after the first global approvals in Western markets. The decisions by the Japanese Ministry of Health, Labour and ... More »

Bookmark?Remove?

Roche ‘highly encouraged’ by Tecentriq results in breast cancer

ZURICH (Reuters) – Swiss drugmaker Roche said on Monday that a trial showed its immunotherapy Tecentriq plus the chemotherapy Abraxane significantly reduced the risk of disease worsening or death in people with metastatic triple negative breast cancer. The com... More »

Bookmark?Remove?

U.S. approves first marijuana plant-derived drug for epilepsy

(Reuters) – The U.S. health regulator approved GW Pharmaceuticals Plc’s epilepsy treatment on Monday, making it the first cannabis-based drug to win approval in the country and opening floodgates for more research into the medicinal properties of cannabis. The... More »

Bookmark?Remove?

Pfizer’s breast cancer drug combo falls short of survival goal

(Reuters) – Pfizer Inc said on Monday a combination of its breast cancer drug, Ibrance, and another drug was not statistically significant in extending overall survival in certain patients, the secondary goal of a late-stage trial. Ibrance is Pfizer’s blockbus... More »

Bookmark?Remove?

Mixed results for Bristol/Nektar combination in cancer trial

Chicago (Reuters) – Mixed results over the weekend from closely watched studies combining Bristol-Myers Squibb Co’s cancer immunotherapy with Nektar Therapeutics experimental drug NKTR-214, led at least one Wall Street analyst to reassess expectations. Bristol... More »

Bookmark?Remove?

FDA wants to shorten new drug monopolies to cut costs

CHICAGO (Reuters) – In an effort to increase competition and bring down prescription drug prices, FDA Commissioner Dr. Scott Gottlieb wants to speed approval times for rivals to promising new first-to-market medicines. The U.S. Food and Drug Administration chi... More »

Bookmark?Remove?

FDA chief outlines new ways to speed cancer drug approvals

CHICAGO (Reuters) – The U.S. Food and Drug Administration is taking steps to streamline the approval process for cancer drugs, reviewing clinical trial data up front to make sure applications companies submit are complete. The new approach, outlined on Saturda... More »

Bookmark?Remove?

Loxo Oncology posts improved results for newest cancer drug

CHICAGO (Reuters) – An experimental cancer drug from Loxo Oncology performed even better in patients with a rare mutation of the RET gene than previously reported, according to updated results from an early stage clinical trial presented on Saturday. Last mont... More »